Ablynx appoints Edwin Moses as CEO
Edwin is a business leader with a successful track record in creating company value and attracting finance, both in the private and public arena. He is internationally experienced in the life science industry, having spent extended periods in Germany, UK and Italy as well as having had extensive business activities in the USA. Over the past five years he has made a substantial contribution at Board level (primarily as Chairman) to over 15 European life sciences companies. Prior to this, as CEO and then Chairman of Oxford Asymmetry International (OAI), he successfully grew the Company between 1993 and 1998 from four people to 250 people, through several venture capital financing rounds then to a full listing on the London Stock Exchange in 1998. He then led the cross border sale of OAI to Evotec Biosystems AG two years later.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.